Authors
Loading...
Analysis reveals that DOT1L and menin inhibitors alter DNA damage response in acute myeloid leukemia, suggesting new therapeutic vulnerabilities to PARP inhibitors.
Fung et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: